Decreased expression of ferroportin in prostate cancer Corrigendum in /10.3892/ol.2021.12518

Xue,Dong; Zhou,Cui‑Xing; Shi,Yun‑Bo; Lu,Hao; He,Xiao‑Zhou

doi:10.3892/ol.2015.3363

August-2015 Volume 10 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2015 Volume 10 Issue 2

Full Size Image

Article

Decreased expression of ferroportin in prostate cancer

Corrigendum in: /10.3892/ol.2021.12518

Authors:
- Dong Xue
- Cui‑Xing Zhou
- Yun‑Bo Shi
- Hao Lu
- Xiao‑Zhou He
View Affiliations / Copyright

Affiliations: Department of Urology, Third Affiliated Hospital, Suzhou University, Changzhou, Jiangsu 213003, P.R. China, Foreign Languages School, Changzhou Institute of Technology, Changzhou, Jiangsu 213002, P.R. China
Pages: 913-916
|
Published online on: June 11, 2015

https://doi.org/10.3892/ol.2015.3363
Expand metrics +

Abstract

The present study examined the expression levels of ferroportin, a transmembrane protein that transports iron from the inside of a cell to the outside, in the prostate cancer PC3, DU145 and LNCAP cell lines, in the normal prostate RWPE2 cell line, and in tissue samples from different differentiation stages of prostatic carcinoma and prostatic hyperplasia. The study also investigated the role of ferroportin protein expression in the diagnosis and prognosis of prostate cancer. Reverse transcription‑quantitative polymerase chain reaction and western blot analysis were employed to measure the mRNA and protein expression levels of ferroportin in the PC3, DU145, LNCAP and RWPE2 cells. Immunohistochemistry was used to determine ferroportin protein expression in the prostate cancer and prostatic hyperplasia tissues. Compared with the normal prostate RWPE2 cells, ferroportin protein expression was significantly lower in the prostate cancer PC3, DU145 and LNCAP cells (P<0.05). Compared with the prostatic hyperplasia tissues, ferroportin protein expression was significantly reduced in the prostate cancer tissues (P<0.05). Overall, the expression levels of ferroportin in the prostate cancer tissues were lower than those in the normal prostate tissues, which may provide valuable clinical information for the diagnosis and prediction of disease progression in prostate cancer, and may indicate a potential therapeutic target for treating prostate cancer by regulating iron metabolism.

View Figures

View References

1	Ye L, Kynaston HG and Jiang WG: Bone metastasis in prostate cancer: Molecular and cellular mechanisms. Int J Mol Med. 20:103–111. 2007.PubMed/NCBI
2	Aihara M, Lebovita RM, Wheeler TM, Kinner BM, Ohori M and Scardino PT: Prostate specific antigen and gleason grade: An immunohistochemical study of prostate cancer. J Urol. 151:1558–1564. 1994.PubMed/NCBI
3	Melchior SW and Brawer MK: Role of transrectal ultrasound and prostate biopsy. J Clin Ultrasound. 24:463–471. 1996. View Article : Google Scholar : PubMed/NCBI
4	Torti SV and Torti FM: Ironing out cancer. Cancer Res. 71:1511–1514. 2011. View Article : Google Scholar : PubMed/NCBI
5	Nemeth E and Ganz T: Regulation of iron metabolism by hepcidin. Annu Rev Nutr. 26:323–342. 2006. View Article : Google Scholar : PubMed/NCBI
6	Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK and Ganz T: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of iron regulatory hormone hepcidin. J Clin Invest. 113:1271–1276. 2004. View Article : Google Scholar : PubMed/NCBI
7	Pogribny IP: Ferroportin and hepcidin: a new hope in diagnosis, prognosis and therapy for breast cancer. Breast Cancer Res. 12:3142010. View Article : Google Scholar : PubMed/NCBI
8	Pinnix ZK, Miller LD, Wang W, et al: Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med. 2:43–56. 2010. View Article : Google Scholar
9	Gleason DF: Histologic grading of prostatic carcinoma. Pathology of the prostate (Contemporary Issues in Surgical Pathology). Bostwick MD and David G: Churchill Livingstone; New York: pp. 83–87. 1990
10	Cairo G, Bernuzzi F and Recalcati S: A precious metal: Iron, an essential nutrient for all cells. Genes Nutr. 1:25–39. 2006. View Article : Google Scholar : PubMed/NCBI
11	Merlot AM, Kalinowski DS and Richardson DR: Novel chelators for cancer treatment: Where are we now? Antioxid Redox Signal. 18:973–1006. 2013. View Article : Google Scholar : PubMed/NCBI
12	Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, et al: Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med. 2:43–56. 2010. View Article : Google Scholar
13	Song S, Christova T, Perusini S, Alizadeh S, Bao RY, Miller BW, Hurren R, Jitkova Y, Gronda M, Isaac M, et al: Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers. Cancer Res. 71:7628–6737. 2011. View Article : Google Scholar : PubMed/NCBI
14	Tanno T, Rabel A, Alleyne M, Lee YT, Dahut WL, Gulley JL and Miller JL: Hepcidin, anaemia and prostate cancer. BJU Int. 107:678–9. 2011. View Article : Google Scholar : PubMed/NCBI
15	De Domenico I, Ward DM, Langelier C, Vaughn MB, Nemeth E, Sundquist WI, Ganz T, Musci G and Kaplan J: The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell. 18:2569–2578. 2007. View Article : Google Scholar : PubMed/NCBI
16	Ellervik C, Tybjaerg-Hansen A and Nordestgaard BG: Risk of cancer by transferrin saturation levels and haemochromatosis genotype: Population-based study and meta-analysis. J Intern Med. 271:51–63. 2012. View Article : Google Scholar : PubMed/NCBI